Companies: 10,795·Total market cap: $144.5T
Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc.

EPRXFOTCHealthcare
$3.04
$-0.20(-6.17%)
Market Cap$108291792
P/E Ratio
52W High$6.7764
52W Low$2.9341

Eupraxia Pharmaceuticals Inc. (EPRXF) Revenue

Annual & quarterly revenue history · segment & region breakdown

EPRXF · revenue · updated Jun 9, 2026

Core revenue metrics

Eupraxia Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
21 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Eupraxia Pharmaceuticals Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
EPRXF revenue by year · EPRXF revenue history · EPRXF annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Eupraxia Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Eupraxia Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Eupraxia Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

EPRXF revenue · 4 questions

EPRXF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

EPRXF revenueEPRXF annual revenuewhat is EPRXF revenueEPRXF TTM revenue

Source: FMP · Eupraxia Pharmaceuticals Inc. SEC filings · GAAP · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026